Biotech: Blood samples are raw materials for virus research and development. by Amy Stulick, Staff Reporter As pharmaceutical labs race to develop a vaccine for COVID-19, biomaterial for researchers has become increasingly valuable. That works to the advantage of Sanguine Biosciences in Sherman Oaks, which provides blood, tissue, plasma, and other biologic material for R&D.
After recovering from Covid-19 in April, Tom Hanks was so chuffed by the prospect of his plasma being used for medical science that he suggested calling the results a “Hank-cine.” He is not alone. Other former patients are equally enthusiastic about donating blood to the research effort.
Study-patient recruitment and retention continue to be significant challenges in medical research, and even more so, during the COVID-19 pandemic. The at-home isolation and social distancing orders for millions of Americans is a vital element to slow the COVID-19 pandemic, but the global pandemic has the potential to disrupt and delay vital research.
In 2000, Malcolm Gladwell’s The Tipping Point became a runaway bestseller by describing the factors that fuel an epidemic, and how the world suddenly becomes a different place as it reaches the inflection point. He discusses epidemics as spreading quickly like a virus, causing people to start behaving differently, triggering contagiousness, whether it applies to fashion trends, the uptake of cell phones, or the spread of disease.
The global search for a treatment targeting the novel coronavirus has led to an unlikely potential savior: a cocoa-colored llama named Winter, whose blood could hold a weapon to blunt the virus. She lives at a research farm in Belgium with about 130 other llamas and alpacas.
WBZ | CBS Boston – Lara Woolfson’s COVID-19 story and her participation with Sanguine for her in-home blood sample collection. Transcript: Headline News: Live from the Channel 4 Studios in Boston, this is WBZ news at 5:30. Liam Martin: Well for a photographer from Boston who has already recovered from the coronavirus is hoping that her fight with it will help others recover as well.
Antibodies in recovered victums’ blood may hold key to COVID-19 cure In the race to develop treatments for the coronavirus, two California biotech companies are teaming up to collect blood samples from people who have recovered from COVID-19 — with the hope that antibodies produced by their immune system after being infected can provide the key to developing a drug or vaccine.
Phlebotomist Teams Assisting Researchers in Select Cities Transcript: Trace Gallagher: Well, phlebotomists just may be the unsung heroes in the fight against COVID-19. Teams of licensed phlebotomists in select cities are suiting up in protective gear and masks and heading into homes of former coronavirus patients.
Transcript: Logan Plaster: Founder and CEO of Sanguine Biosciences. Brian, why don’t you to come on in? Great to see you. Brian Neman: Great to see you. How are you? Logan Plaster: Good, good, good. Take a seat. Grab the microphone and happy to have you joining us live in the Startup Health studio.
In an urgent effort to develop a potential vaccine and medicine for COVID-19, a San Francisco drug company on Friday asked residents of Boston and five other US hot spots in the coronavirus epidemic to donate blood if they have recovered from the disease.